In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Centessa Pharmaceuticals Announces $300M Financing Agreement with Oberland Capital

Executive Summary

Centessa Pharmaceuticals plc (discovering, developing and delivering medicines to patients) entered into a $300M financing agreement with funds managed by Oberland Capital Management. Oberland Capital will purchase up to $300M of 6-year, interest-only, senior secured notes from the company under the following terms; $75M funded October 4, 2021 (First Purchase Date); $125M available to be funded in tranches of $75 million and $50M within 24 months of First Purchase Date at the option of the company; $100M available to fund M&A, in-licensing, or other strategic transactions, at the option of the company and Oberland Capital; The notes are interest-only for the full 6-year term; principal on the notes will be due October 4, 2027, with certain contingent and capped payments due up to ten years from First Purchase Date; Flexible structure with no financial covenants. This facility enables to advance the company’s pipeline of clinical and pre-clinical programs and enables the company to pursue strategic business development opportunities.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies